AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16171866 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrimethamine/sulfadiazine
Number of subjects: 59
Study 16171866 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim/sulfamethoxazole
Number of subjects: 59
Study 16171866 — intervention group
Group type: COMPARATOR
Intervention: Control (not applicable)
Number of subjects: 59
Study 12766123 — intervention group
Group type: EXPERIMENTAL
Intervention: Actovegin plus 0.02% (wt/wt) hEGF
Number of subjects: 61
Study 12766123 — intervention group
Group type: EXPERIMENTAL
Intervention: Actovegin plus 0.04% (wt/wt) hEGF
Number of subjects: 61
Study 12766123 — intervention group
Group type: COMPARATOR
Intervention: Actovegin 5% cream (Control)
Number of subjects: 61
Study 10655920 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate in propylene glycol formulation
Number of subjects: 20
Study 10655920 — intervention group
Group type: COMPARATOR
Intervention: Etomidate in lipid emulsion formulation
Number of subjects: 20
Study 8877243 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal decongestant-antihistamine (nasal oxymetazolone and oral syrup containing brompheniramine and phenylpropanolamine)
Number of subjects: 0
Study 8877243 — intervention group
Group type: COMPARATOR
Intervention: Placebo (nasal saline and oral syrup)
Number of subjects: 0
Study 1688268 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulphasalazine
Number of subjects: 39
Study 1688268 — intervention group
Group type: COMPARATOR
Intervention: Delagil
Number of subjects: 39
Study 6356280 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxacillin plus rifampin
Number of subjects: 56
Study 6356280 — intervention group
Group type: COMPARATOR
Intervention: Oxacillin alone
Number of subjects: 56
Study 30819162 — intervention group
Group type: COMPARATOR
Intervention: STarT Back Tool (STarT-G) classification
Number of subjects: 294
Study 30819162 — intervention group
Group type: COMPARATOR
Intervention: Prognostic model including STarT-Classification, global health, and disability at baseline
Number of subjects: 294
Study 29551346 — intervention group
Group type: EXPERIMENTAL
Intervention: Desensitizing-containing 10% carbamide peroxide gel (3% potassium nitrate and 0.2% sodium fluoride)
Number of subjects: 60
Study 29551346 — intervention group
Group type: COMPARATOR
Intervention: Desensitizing-free 10% carbamide peroxide gel
Number of subjects: 60
Study 26750677 — intervention group
Group type: EXPERIMENTAL
Intervention: Macintosh (MC) laryngoscope
Number of subjects: 60
Study 26750677 — intervention group
Group type: EXPERIMENTAL
Intervention: McGrath (MG) laryngoscope
Number of subjects: 60
Study 26750677 — intervention group
Group type: EXPERIMENTAL
Intervention: Truview™ laryngoscope
Number of subjects: 60
Study 24509697 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic tablets containing L. reuteri strain (Prodentis)
Number of subjects: 38
Study 24509697 — intervention group
Group type: COMPARATOR
Intervention: No probiotic tablet treatment (Control Group 2)
Number of subjects: 38
Study 22103571 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 100
Study 22103571 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 100
Study 21051677 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose interferon-{alpha} treatment for 4 weeks
Number of subjects: 46
Study 21051677 — intervention group
Group type: COMPARATOR
Intervention: Low-dose interferon-{alpha} treatment for 4 weeks
Number of subjects: 46
Study 17097342 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-rTMS (90% of resting motor threshold, 10 Hz, 450 pulses/day for 10 consecutive days)
Number of subjects: 13
Study 17097342 — intervention group
Group type: COMPARATOR
Intervention: Sham-rTMS
Number of subjects: 13
Study 17097342 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-rTMS
Number of subjects: 13
Study 16401946 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol A (Ceftriaxone, Metronidazole, and aminoglycoside)
Number of subjects: 59
Study 16401946 — intervention group
Group type: COMPARATOR
Intervention: Protocol B (Ceftriaxone and Metronidazole)
Number of subjects: 59
Study 16401946 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol A
Number of subjects: 59
Study 16401946 — intervention group
Group type: COMPARATOR
Intervention: Protocol B
Number of subjects: 59
Study 12100574 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA)
Number of subjects: 28
Study 12100574 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 12100574 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline PBC patients
Number of subjects: 28
Study 10539749 — intervention group
Group type: EXPERIMENTAL
Intervention: Prepared Meal Plan (PMP; n = 244)
Number of subjects: 491
Study 10539749 — intervention group
Group type: COMPARATOR
Intervention: Self-Selected Diet (SSD; n = 247)
Number of subjects: 491
Study 7573849 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate 5 mg aerosol
Number of subjects: 114
Study 7573849 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen syrup
Number of subjects: 114
Study 7573849 — intervention group
Group type: COMPARATOR
Intervention: Placebo syrup
Number of subjects: 114
Study 7573849 — intervention group
Group type: COMPARATOR
Intervention: Placebo aerosol
Number of subjects: 114
Study 2154942 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofragmentable anastomosis ring (BAR)
Number of subjects: 59
Study 2154942 — intervention group
Group type: COMPARATOR
Intervention: Suture technique
Number of subjects: 59
Study 2154942 — intervention group
Group type: COMPARATOR
Intervention: Staple technique
Number of subjects: 59
Study 2154942 — intervention group
Group type: COMPARATOR
Intervention: All techniques (BAR, suture, staple)
Number of subjects: 59
Study 2154942 — intervention group
Group type: EXPERIMENTAL
Intervention: BAR
Number of subjects: 59
Study 7428417 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefruside
Number of subjects: 20
Study 7428417 — intervention group
Group type: EXPERIMENTAL
Intervention: Debrisoquin
Number of subjects: 20
Study 7428417 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of debrisoquin and mefruside
Number of subjects: 20
Study 7428417 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 30796587 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoral scan (IOS)
Number of subjects: 19
Study 30796587 — intervention group
Group type: COMPARATOR
Intervention: Conventional impression (CI)
Number of subjects: 19
Study 28657492 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 22
Study 28657492 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 28011809 — intervention group
Group type: EXPERIMENTAL
Intervention: Low TT group receiving 430 mg of 70% pure TTs (300 mg TT)
Number of subjects: 0
Study 28011809 — intervention group
Group type: EXPERIMENTAL
Intervention: High TT group receiving 860 mg of 70% pure TTs (600 mg TT)
Number of subjects: 0
Study 28011809 — intervention group
Group type: COMPARATOR
Intervention: Placebo group receiving 860 mg olive oil
Number of subjects: 0
Study 24961753 — intervention group
Group type: EXPERIMENTAL
Intervention: Evacetrapib 600 mg
Number of subjects: 0
Study 24961753 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21983371 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone infusion (n = 55)
Number of subjects: 79
Study 19578220 — intervention group
Group type: EXPERIMENTAL
Intervention: Plapheron LB in dose of 0.028 mg/kg two times a day sublingually for ten days
Number of subjects: 94
Study 19578220 — intervention group
Group type: COMPARATOR
Intervention: Ordinary program of intensive therapy
Number of subjects: 94
Study 17518892 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-centred teaching program
Number of subjects: 123
Study 17518892 — intervention group
Group type: COMPARATOR
Intervention: Illustrated poster teaching
Number of subjects: 123
Study 15041602 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous fascia iliaca compartment block (FICB) with ropivacaine 0.2%
Number of subjects: 20
Study 15041602 — intervention group
Group type: COMPARATOR
Intervention: Saline 0.9% (control)
Number of subjects: 20
Study 11314833 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular metaraminol (0.1 mg x kg(‐1))
Number of subjects: 52
Study 11314833 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous boluses (0.01 mg x kg(‐1))
Number of subjects: 52
Study 11314833 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion (0.05 mg x kg(‐1) x h(‐1))
Number of subjects: 52
Study 11314833 — intervention group
Group type: COMPARATOR
Intervention: Spinal anaesthesia
Number of subjects: 52
Study 9041052 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin‐like growth factor‐I (IGF‐I) administration, 40 micrograms/kg of body weight/day, for 1 week
Number of subjects: 22
Study 9041052 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) therapy, 0.125 IU/kg of body weight/week for the first month, then 0.250 IU/kg of body weight/week, for 24 months
Number of subjects: 22
Study 7957464 — intervention group
Group type: EXPERIMENTAL
Intervention: Wide‐spectrum antibiotic therapy with macrolide and mepartricin
Number of subjects: 77
Study 7957464 — intervention group
Group type: COMPARATOR
Intervention: Local estrogen therapy
Number of subjects: 77
Study 3479447 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauner's open method
Number of subjects: 0
Study 3479447 — intervention group
Group type: COMPARATOR
Intervention: Brown's closed method
Number of subjects: 0
Study 28385953 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety promotion intervention (n=91)
Number of subjects: 277
Study 28385953 — intervention group
Group type: COMPARATOR
Intervention: Attention-control group (n=186)
Number of subjects: 277
Study 28228162 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol/glycopyrronium (IND/GLY) 110/50 μg fixed-dose LABA/LAMA combination
Number of subjects: 404
Study 28228162 — intervention group
Group type: COMPARATOR
Intervention: Tiotropium 18 μg
Number of subjects: 404
Study 26237742 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACWY-TT booster dose
Number of subjects: 872
Study 26237742 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACWY-DT
Number of subjects: 872
Study 26237742 — intervention group
Group type: COMPARATOR
Intervention: MenACWY-TT
Number of subjects: 872
Study 24192207 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene (not specified dosage or duration)
Number of subjects: 1245
Study 24192207 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 1245
Study 21068346 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mL orange juice
Number of subjects: 24
Study 21068346 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mL control drink plus hesperidin (CDH)
Number of subjects: 24
Study 21068346 — intervention group
Group type: COMPARATOR
Intervention: 500 mL control drink plus placebo (CDP)
Number of subjects: 24
Study 18978616 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body low-intensity resistance training with slow movement and tonic force generation (LST)
Number of subjects: 36
Study 18978616 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity resistance training with normal speed (HN)
Number of subjects: 36
Study 18978616 — intervention group
Group type: COMPARATOR
Intervention: Sedentary control group (CON)
Number of subjects: 36
Study 14627972 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent hyperkalaemic undiluted warm blood anterograde cardioplegia (AC)
Number of subjects: 69
Study 14627972 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous hyperkalaemic undiluted warm blood retrograde cardioplegia (RC)
Number of subjects: 69
Study 14627972 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent, hyperkalaemic, diluted cold blood (15 degrees C), anterograde cardioplegia (CC)
Number of subjects: 69
Study 9921604 — intervention group
Group type: EXPERIMENTAL
Intervention: Methods of extracting estimates of log hazard ratio and its variance
Number of subjects: 0
Study 9050559 — intervention group
Group type: EXPERIMENTAL
Intervention: ClearView Uterine Manipulator
Number of subjects: 50
Study 9050559 — intervention group
Group type: COMPARATOR
Intervention: Cohen cannula
Number of subjects: 50
Study 2235671 — intervention group
Group type: EXPERIMENTAL
Intervention: Single bolus injection of heparin (3000 to 12,000 U) administered prior to hemodialysis
Number of subjects: 17
Study 2235671 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 17
Study 2235671 — intervention group
Group type: COMPARATOR
Intervention: Individualized dose
Number of subjects: 17
Study 28810 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 0
Study 28810 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol
Number of subjects: 0
Study 28810 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol
Number of subjects: 0
Study 28810 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol
Number of subjects: 0
Study 28810 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol
Number of subjects: 0
Study 28810 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendrofluazide
Number of subjects: 0
Study 28810 — intervention group
Group type: COMPARATOR
Intervention: Thiazide diuretic (Bendrofluazide)
Number of subjects: 0
Study 31542876 — intervention group
Group type: EXPERIMENTAL
Intervention: PAM50 subtypes
Number of subjects: 1723
Study 31542876 — intervention group
Group type: EXPERIMENTAL
Intervention: Luminal B subtype
Number of subjects: 1723
Study 31542876 — intervention group
Group type: EXPERIMENTAL
Intervention: 13-gene hypoxia signature
Number of subjects: 1723
Study 31335301 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethinylestradiol/levonorgestrel (EE/LNG) 30/150 μg co-administered with atazanavir/cobicistat (ATV/COBI) 300/150 mg
Number of subjects: 6
Study 31335301 — intervention group
Group type: COMPARATOR
Intervention: Control group (Atazanavir/cobicistat alone)
Number of subjects: 6
Study 28072447 — intervention group
Group type: COMPARATOR
Intervention: Standard diet
Number of subjects: 126
Study 28072447 — intervention group
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid-enriched diet (ProSure®), 600 kcal with 2.2 g eicosapentaenoic acid, for 7 days before and 21 days after surgery
Number of subjects: 126
Study 26103654 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug treatment + patient education
Number of subjects: 100
Study 26103654 — intervention group
Group type: COMPARATOR
Intervention: Drug treatment only
Number of subjects: 100
Study 23683475 — intervention group
Group type: COMPARATOR
Intervention: Clinical model without kallikrein markers
Number of subjects: 392
Study 23683475 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical model with kallikrein markers
Number of subjects: 392
Study 21243370 — intervention group
Group type: EXPERIMENTAL
Intervention: PVD and removal of the ILM (group II)
Number of subjects: 40
Study 21243370 — intervention group
Group type: COMPARATOR
Intervention: Surgical induction of posterior vitreous detachment (PVD) (group I)
Number of subjects: 40
Study 18976313 — intervention group
Group type: EXPERIMENTAL
Intervention: AcrySof IQ IOLs
Number of subjects: 60
Study 18976313 — intervention group
Group type: COMPARATOR
Intervention: AcrySof Natural IOLs
Number of subjects: 60
Study 18004124 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (100-400 mg/d)
Number of subjects: 429
Study 18004124 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 429
Study 15138475 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen treatment for 2 years
Number of subjects: 167
Study 15138475 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 167
Study 15138475 — intervention group
Group type: COMPARATOR
Intervention: Untreated patients with cyclin D1 high tumors
Number of subjects: 167
Study 11472654 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate provisional protocol for single-tooth implant replacement
Number of subjects: 24
Study 9603636 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem
Number of subjects: 105
Study 9603636 — intervention group
Group type: COMPARATOR
Intervention: Imipenem/cilastatin
Number of subjects: 105
Study 8091964 — intervention group
Group type: EXPERIMENTAL
Intervention: CMD women
Number of subjects: 168
Study 8091964 — intervention group
Group type: COMPARATOR
Intervention: CMD men
Number of subjects: 168
Study 3401061 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal gastric vagotomy with closure (PGV)
Number of subjects: 78
Study 3401061 — intervention group
Group type: COMPARATOR
Intervention: Closure alone
Number of subjects: 78
Study 31783004 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B: 3.6 mL of articaine and 1 mL of dexamethasone (4‐mg/mL solution) with 1 mL of saline solution
Number of subjects: 60
Study 31783004 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C: 3.6 mL of articaine with 2 mL of dexamethasone (8‐mg/mL solution)
Number of subjects: 60
Study 31783004 — intervention group
Group type: COMPARATOR
Intervention: Group A: 3.6 mL of articaine mixed with 2 mL of saline solution
Number of subjects: 60
Study 30924413 — intervention group
Group type: EXPERIMENTAL
Intervention: Home ovulation test
Number of subjects: 0
Study 30924413 — intervention group
Group type: COMPARATOR
Intervention: Predicted day of ovulation based on average menstrual cycle
Number of subjects: 0
Study 27775471 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week diet and physical activity intervention (n = 17)
Number of subjects: 32
Study 27775471 — intervention group
Group type: COMPARATOR
Intervention: Assessment-only control group (n = 15)
Number of subjects: 32
Study 24888221 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flexion TKA
Number of subjects: 59
Study 24888221 — intervention group
Group type: COMPARATOR
Intervention: Standard TKA
Number of subjects: 59
Study 23617871 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation in recovery-oriented activities
Number of subjects: 240
Study 23617871 — intervention group
Group type: EXPERIMENTAL
Intervention: Syringe exchange program (SEP) participation
Number of subjects: 240
Study 21267039 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal epidural injections with local anesthetic (lidocaine 0.5% 10 mL)
Number of subjects: 120
Study 21267039 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal epidural injections with 9 mL of 0.5% lidocaine mixed with 1 mL of steroid (either betamethasone [6 mg] or methylprednisolone [40 mg])
Number of subjects: 120
Study 21267039 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful group (patients achieving significant pain relief and functional status improvement)
Number of subjects: 120
Study 19689825 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 Gy in 40 fractions over 8 weeks (arm A)
Number of subjects: 162
Study 19689825 — intervention group
Group type: COMPARATOR
Intervention: 62 Gy in 20 fractions over 5 weeks (arm B)
Number of subjects: 162
Study 17339189 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous peripheral blood stem cell transplantation (PBSCT) after induction and consolidation chemotherapy with BAVC regimen.
Number of subjects: 61
Study 17339189 — intervention group
Group type: COMPARATOR
Intervention: Induction therapy with mitoxantrone, etoposide, and cytarabine (MICE) with or without G-CSF; consolidation therapy with mini-ICE.
Number of subjects: 61
Study 14668149 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback treatment (EMG biofeedback training plus conventional exercise programme)
Number of subjects: 36
Study 14668149 — intervention group
Group type: COMPARATOR
Intervention: Conventional exercise programme only (Control)
Number of subjects: 36
Study 11295361 — intervention group
Group type: EXPERIMENTAL
Intervention: Dealcoholized red wine
Number of subjects: 18
Study 11295361 — intervention group
Group type: COMPARATOR
Intervention: Red wine
Number of subjects: 18
Study 11295361 — intervention group
Group type: COMPARATOR
Intervention: White wine
Number of subjects: 18
Study 11295361 — intervention group
Group type: COMPARATOR
Intervention: Alcohol-containing beverages (red and white wine)
Number of subjects: 18
Study 11295361 — intervention group
Group type: COMPARATOR
Intervention: All beverages
Number of subjects: 18
Study 9496496 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilatation (DILAT Group)
Number of subjects: 40
Study 9496496 — intervention group
Group type: COMPARATOR
Intervention: Esophagocardiomyotomy (Group OP)
Number of subjects: 40
Study 9496496 — intervention group
Group type: EXPERIMENTAL
Intervention: Both procedures
Number of subjects: 40
Study 7922793 — intervention group
Group type: EXPERIMENTAL
Intervention: Injectable salmon calcitonin (50 IU)
Number of subjects: 6
Study 7922793 — intervention group
Group type: EXPERIMENTAL
Intervention: Injectable calcitonin analogue ASC 710 (0.2 mg)
Number of subjects: 6
Study 7922793 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ASC 710 (20 mg)
Number of subjects: 6
Study 3165972 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotretinoin
Number of subjects: 40
Study 3165972 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate
Number of subjects: 40
Study 29516490 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 0
Study 29516490 — intervention group
Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 0
Study 29151561 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive psychotherapy program (n=28)
Number of subjects: 57
Study 29151561 — intervention group
Group type: COMPARATOR
Intervention: Usual treatment in community centers (n=29)
Number of subjects: 57
Study 25935793 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 months of adjuvant trastuzumab
Number of subjects: 481
Study 25935793 — intervention group
Group type: COMPARATOR
Intervention: 6 months of adjuvant trastuzumab
Number of subjects: 481
Study 23968366 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured lifestyle and medication treatment by practice nurses with additional self‐monitoring
Number of subjects: 179
Study 23968366 — intervention group
Group type: COMPARATOR
Intervention: Structured lifestyle and medication treatment by practice nurses without additional self‐monitoring
Number of subjects: 179
Study 23968366 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of or dose change in lipid lowering or antihypertensive medications
Number of subjects: 179
Study 20881473 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based, multicomponent HIV and reproductive health intervention, with exposure to at least 10 intervention sessions.
Number of subjects: 4684